Within the last decade the field of therapeutics have witnessed an evolution in the treatment armamentarium of rheumatoid arthritis with the lead of the Tumor necrosis factor inhibitors (TNF-I) as the first line biologic drugs (Burmester GR et al. 2012; Wolfe and Michaud 2010; Nozaki et al. 2013; Mohammed et al. 2014; Nam et al. 2010; Hetland et al. 2010; Gartlehner et al. 2006; Wolfe and Michaud 2010; Gaujoux-Viala et al. 2010). This evidence concerns the gene TNF and rheumatoid arthritis.